Ochsner Medical Center, New Orleans, LA, USA.
Ochsner Medical Center, New Orleans, LA, USA.
Prog Cardiovasc Dis. 2021 May-Jun;66:80-85. doi: 10.1016/j.pcad.2021.06.002.
Atrial Fibrillation (AF) and heart failure (HF) with reduced ejection fraction (HFrEF) frequently coexist, resulting in significant morbidity and mortality. Therapeutic options for patients with AF and HFrEF are limited due to few antiarrhythmic drug (AAD) choices and historically equivocal effects of procedural interventions on mortality. However, recent randomized trials examining catheter ablation (CA) in AF patients with HFrEF have shown a beneficial effect on arrhythmic burden and HF symptoms, as well as an improvement in mortality. This review focuses on the role of CA for AF patients with HFrEF.
心房颤动（AF）和射血分数降低的心力衰竭（HF）经常同时存在，导致发病率和死亡率显著增加。由于抗心律失常药物（AAD）选择有限，以及程序性介入对死亡率的影响历来存在争议，因此 AF 和 HFrEF 患者的治疗选择有限。然而，最近检查 HFrEF 合并 AF 患者导管消融（CA）的随机试验显示，CA 对心律失常负担和 HF 症状有有益影响，并改善了死亡率。这篇综述重点介绍了 CA 在 HFrEF 合并 AF 患者中的作用。
